
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/536881/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nature Genetics, 2000, 26, 103-105.	21.4	397
2	Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nature Genetics, 2015, 47, 535-538.	21.4	274
3	Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood, 2011, 117, 6673-6680.	1.4	263
4	MYH9-Related Disease. Medicine (United States), 2003, 82, 203-215.	1.0	255
5	Mutations in the 5′ UTR of ANKRD26, the Ankirin Repeat Domain 26 Gene, Cause an Autosomal-Dominant Form of Inherited Thrombocytopenia, THC2. American Journal of Human Genetics, 2011, 88, 115-120.	6.2	200
6	Recent advances in the understanding and management of <i>MYH9</i> â€related inherited thrombocytopenias. British Journal of Haematology, 2011, 154, 161-174.	2.5	196
7	Age- And Sex-Related Variations in Platelet Count in Italy: A Proposal of Reference Ranges Based on 40987 Subjects' Data. PLoS ONE, 2013, 8, e54289.	2.5	190
8	Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood, 2001, 97, 1330-1335.	1.4	174
9	Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Human Mutation, 2008, 29, 409-417.	2.5	172
10	New roles for mean platelet volume measurement in the clinical practice?. Platelets, 2016, 27, 607-612.	2.3	164
11	<i>MYH9</i> -Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype-Phenotype Correlations. Human Mutation, 2014, 35, 236-247.	2.5	154
12	ANKRD26-related thrombocytopenia and myeloid malignancies. Blood, 2013, 122, 1987-1989.	1.4	145
13	Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood, 2010, 116, 5832-5837.	1.4	141
14	Thrombopoietin levels in patients with primary and reactive thrombocytosis. British Journal of Haematology, 1997, 99, 281-284.	2.5	131
15	Spectrum of the Mutations in Bernard-Soulier Syndrome. Human Mutation, 2014, 35, 1033-1045.	2.5	124
16	Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. Journal of Thrombosis and Haemostasis, 2008, 6, 1900-1907.	3.8	120
17	High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Annals of Hematology, 2010, 89, 591-596.	1.8	115
18	Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. Blood, 2014, 124, e4-e10.	1.4	112

CARLO L BALDUINI

#	Article	IF	CITATIONS
19	Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thrombosis and Haemostasis, 2004, 91, 129-140.	3.4	105
20	Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIb (Bolzano mutation). Haematologica, 2012, 97, 82-88.	3.5	99
21	Genetics, clinical and pathological features of glomerulonephrites associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). American Journal of Kidney Diseases, 2003, 41, 95-104.	1.9	94
22	Thrombocytopenia, Giant Platelets, and Leukocyte Inclusion Bodies (May-Hegglin Anomaly): Clinical and Laboratory Findings. American Journal of Medicine, 1998, 104, 355-360.	1.5	93
23	Clinical and pathogenic features of <i>ETV6</i> -related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica, 2016, 101, 1333-1342.	3.5	92
24	Inherited thrombocytopenias: from genes to therapy. Haematologica, 2002, 87, 860-80.	3.5	92
25	Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica, 2003, 88, 582-92.	3.5	91
26	Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations. Haematologica, 2011, 96, 417-423.	3.5	90
27	Inherited thrombocytopenias frequently diagnosed in adults. Journal of Thrombosis and Haemostasis, 2013, 11, 1006-1019.	3.8	87
28	Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 2131-2136.	3.8	86
29	Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. British Journal of Haematology, 2013, 162, 112-119.	2.5	86
30	Platelet count and aging. Haematologica, 2014, 99, 953-955.	3.5	86
31	Genetics of familial forms of thrombocytopenia. Human Genetics, 2012, 131, 1821-1832.	3.8	85
32	Heavy chain myosin 9-related disease (MYH9-RD): Neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thrombosis and Haemostasis, 2010, 103, 826-832.	3.4	81
33	Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thrombosis and Haemostasis, 2009, 102, 90-96.	3.4	76
34	Proplatelet formation in heterozygous Bernard‣oulier syndrome type Bolzano. Journal of Thrombosis and Haemostasis, 2009, 7, 478-484.	3.8	73
35	Revealing eltrombopags promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica, 2016, 101, 1479-1488.	3.5	70
36	Analysis of 12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions to thrombocytopenia and thrombocytosis are inherited traits. Haematologica, 2011, 96, 96-101.	3.5	70

CARLO L BALDUINI

#	Article	IF	CITATIONS
37	Correlation between the clinical phenotype of MYH9 -related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics, 2004, 83, 1125-1133.	2.9	69
38	Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrology Dialysis Transplantation, 2008, 23, 2690-2692.	0.7	68
39	A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 2001, 113, 1044-1046.	2.5	67
40	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
41	Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e13-e18.	1.7	64
42	Dominant inheritance of a novel integrin Â3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica, 2009, 94, 663-669.	3.5	64
43	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica, 2014, 99, 1387-1394.	3.5	63
44	Platelet Aggregation in Platelet-Rich Plasma and Whole Blood in 120 Patients with Myeloproliferative Disorders. American Journal of Clinical Pathology, 1991, 95, 82-86.	0.7	59
45	ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization. Blood, 2015, 125, 869-872.	1.4	57
46	Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Lancet Haematology,the, 2015, 2, e465-e473.	4.6	57
47	Diagnosis and Management of Inherited Thrombocytopenias. Seminars in Thrombosis and Hemostasis, 2013, 39, 161-171.	2.7	55
48	Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets, 2007, 18, 579-582.	2.3	53
49	Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica, 2007, 92, 1186-1193.	3.5	53
50	Inherited thrombocytopenias. Hamostaseologie, 2012, 32, 259-270.	1.9	53
51	Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Human Molecular Genetics, 2005, 14, 3169-3178.	2.9	52
52	Inherited thrombocytopenias—recent advances in clinical and molecular aspects. Platelets, 2017, 28, 3-13.	2.3	51
53	Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial. Haematologica, 2020, 105, 820-828.	3.5	51
54	Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica, 2004, 89, 1219-25.	3.5	51

4

#	Article	IF	CITATIONS
55	Altered cytoskeleton organization in platelets from patients with MYH9-related disease. Journal of Thrombosis and Haemostasis, 2005, 3, 1026-1035.	3.8	50
56	Relationship between size and thiazole orange fluorescence of platelets in patients undergoing highâ€dose chemotherapy. British Journal of Haematology, 1999, 106, 202-207.	2.5	49
57	Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and Â-granule deficiency. Haematologica, 2013, 98, 868-874.	3.5	49
58	Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombocytopenia. Thrombosis and Haemostasis, 2013, 109, 263-271.	3.4	49
59	Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool forMYH9-related disorders. British Journal of Haematology, 2002, 117, 164-167.	2.5	47
60	Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable withÂromiplostim. EMBO Molecular Medicine, 2018, 10, 63-75.	6.9	47
61	Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chainÂ9 gene. Human Genetics, 2002, 110, 182-186.	3.8	45
62	Reversal of Thrombin-Induced Deactivation of CD39/ATPDase in Endothelial Cells by HMG-CoA Reductase Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 894-900.	2.4	44
63	The Gene for May-Hegglin Anomaly Localizes to a <1-Mb Region on Chromosome 22q12.3-13.1. American Journal of Human Genetics, 2000, 66, 1449-1454.	6.2	40
64	Loss-of-function mutations in PTPRJ cause a new form of inherited thrombocytopenia. Blood, 2019, 133, 1346-1357.	1.4	40
65	Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome. PLoS ONE, 2012, 7, e35986.	2.5	38
66	Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation. Thrombosis and Haemostasis, 2012, 107, 1188-1189.	3.4	38
67	Inherited thrombocytopenias: an updated guide for clinicians. Blood Reviews, 2021, 48, 100784.	5.7	37
68	A new variant of Bernard-Soulier syndrome characterized by dysfunctional glycoprotein (GP) Ib and severely reduced amounts of GPIX and GPV. British Journal of Haematology, 1998, 103, 1004-1013.	2.5	36
69	High Doses of Romiplostim Induce Proliferation and Reduce Proplatelet Formation by Human Megakaryocytes. PLoS ONE, 2013, 8, e54723.	2.5	36
70	Lessons in platelet production from inherited thrombocytopenias. British Journal of Haematology, 2014, 165, 179-192.	2.5	35
71	Bleeding Tendency of Unknown Origin and Protein Z Levels. Thrombosis Research, 1998, 90, 291-295.	1.7	34
72	Inherited Thrombocytopenias: Molecular Mechanisms. Seminars in Thrombosis and Hemostasis, 2004, 30, 513-523.	2.7	34

#	Article	IF	CITATIONS
73	Clonal chromosome anomalies and propensity to myeloid malignancies in congenital amegakaryocytic thrombocytopenia (OMIM 604498). Haematologica, 2008, 93, 1271-1273.	3.5	34
74	Effect of GPIIb-IIIa complex ligands on calciumion movement and cytoskeleton organization in activated platelets. Biochemical and Biophysical Research Communications, 1988, 154, 258-264.	2.1	33
75	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer, 1991, 68, 2310-2318.	4.1	33
76	Hematopoietic Stem-Cell Transplantation for the Bernard–Soulier Syndrome. Annals of Internal Medicine, 2003, 138, 79.	3.9	33
77	Influence of age, sex and ethnicity on platelet count in five Italian geographic isolates: mild thrombocytopenia may be physiological. British Journal of Haematology, 2012, 157, 384-387.	2.5	33
78	Prevalence of anemia in hospitalized internal medicine patients: Correlations with comorbidities and length of hospital stay. European Journal of Internal Medicine, 2018, 51, 11-17.	2.2	33
79	<i>MYH9</i> related disease: four novel mutations of the tail domain of myosinâ€9 correlating with a mild clinical phenotype. European Journal of Haematology, 2010, 84, 291-297.	2.2	32
80	Megakaryocytes derived from patients with the classical form of Bernard-Soulier syndrome show no ability to extend proplatelets in vitro. Platelets, 2011, 22, 308-311.	2.3	31
81	Title is missing!. Medicine (United States), 2003, 82, 203-215.	1.0	30
82	Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation. Leukemia, 2001, 15, 1885-1891.	7.2	28
83	Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome. Platelets, 2015, 26, 751-757.	2.3	28
84	Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome. Haematologica, 2002, 87, 943-7.	3.5	28
85	Clinic, pathogenic mechanisms and drug testing of two inherited thrombocytopenias, ANKRD26-related Thrombocytopenia and MYH9-related diseases. European Journal of Medical Genetics, 2018, 61, 715-722.	1.3	27
86	Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study. British Journal of Haematology, 2000, 108, 653-659.	2.5	26
87	Autosomal dominant thrombocytopenias with reduced expression of glycoprotein Ia. Thrombosis and Haemostasis, 2006, 95, 483-489.	3.4	26
88	Diagnosis of immune thrombocytopenic purpura in children. Current Opinion in Hematology, 2007, 14, 520-525.	2.5	26
89	MYH9-related disease: Five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations. European Journal of Medical Genetics, 2013, 56, 7-12.	1.3	26
90	Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease. International Journal of Molecular Medicine, 2006, 17, 729-36.	4.0	26

#	Article	IF	CITATIONS
91	Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells. Thrombosis and Haemostasis, 2011, 106, 693-704.	3.4	24
92	Defect of Platelet Aggregation and Adhesion Induced by Autoantibodies Against Platelet Glycoprotein IIIa. Thrombosis and Haemostasis, 1992, 68, 208-213.	3.4	24
93	Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. British Journal of Haematology, 2001, 114, 951-953.	2.5	23
94	Cord blood in vitro expanded CD41+ cells: identification of novel components of megakaryocytopoiesis. Journal of Thrombosis and Haemostasis, 2006, 4, 848-860.	3.8	23
95	Platelet function after in vivo and in vitro treatment with thrombolytic agents. American Journal of Cardiology, 1992, 69, 457-461.	1.6	22
96	International collaboration as a tool for diagnosis of patients with inherited thrombocytopenia in the setting of a developing country. Journal of Thrombosis and Haemostasis, 2012, 10, 1653-1661.	3.8	22
97	Incompatibility for CD31 and human platelet antigens and acute graft-versus-host disease after bone marrow transplantation. British Journal of Haematology, 1999, 106, 723-729.	2.5	21
98	Expression, activation, and subcellular localization of the Rap1 GTPase in cord blood-derived human megakaryocytes. Experimental Cell Research, 2004, 300, 84-93.	2.6	21
99	<i>In vivo </i> Behaviour of Neuraminidase-Treated Rabbit Erythrocytes and Reticulocytes. Acta Haematologica, 1977, 57, 178-187.	1.4	20
100	Acquired cyclic thrombocytopeniaâ€ŧhrombocytosis with periodic defect of platelet function. British Journal of Haematology, 1993, 85, 718-722.	2.5	20
101	von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets. Platelets, 2006, 17, 149-152.	2.3	20
102	Eltrombopag in preparation for surgery in patients with severe <i>MYH9</i> â€ŧelated thrombocytopenia. American Journal of Hematology, 2019, 94, E199-E201.	4.1	20
103	Personalized reference intervals for platelet count reduce the number of subjects with unexplained thrombocytopenia. Haematologica, 2015, 100, e338-e340.	3.5	19
104	Unexplained recurrent venous thrombosis in a patient withMYH9-related disease. Platelets, 2006, 17, 274-275.	2.3	17
105	A population-based study of an Italian genetic isolate reveals that mean platelet volume is not a risk factor for thrombosis. Thrombosis Research, 2012, 129, e8-e13.	1.7	17
106	Behaviour of Young and Old Desialylated Rabbit Erythrocytes in vivo. Hoppe-Seyler's Zeitschrift Für Physiologische Chemie, 1978, 359, 1573-1578.	1.6	16
107	Identification of the first duplication in MYH9-related disease: A hot spot for unequal crossing-over within exon 24 of the MYH9 gene. European Journal of Medical Genetics, 2009, 52, 191-194.	1.3	16
108	Interrelation of platelet aggregation, release reaction and thromboxane A2 production. Biochemical and Biophysical Research Communications, 1988, 156, 822-829.	2.1	14

CARLO L BALDUINI

#	Article	IF	CITATIONS
109	Innovation in the field of thrombocytopenias: achievements since the beginning of the century and promises for the future. Haematologica, 2016, 101, 2-4.	3.5	14
110	Ristocetin-induced Platelet Agglutination Stimulates GPIIb/IIIa-dependent Calcium Influx. Thrombosis and Haemostasis, 1995, 73, 689-692.	3.4	14
111	Why the disorder induced by GATA1 Arg216Gln mutation should be called "X-linked thrombocytopenia with thalassemia―rather than "X-linked gray platelet syndrome― Blood, 2007, 110, 2770-2771.	1.4	13
112	In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: Are they laboratory artefacts?. Platelets, 2009, 20, 131-134.	2.3	11
113	Membrane Sialic Acid and Behaviour in vivo of Rabbit "Stress―Macroreticulocytes. Hoppe-Seyler's Zeitschrift Für Physiologische Chemie, 1977, 358, 1143-1148.	1.6	10
114	Effect of different sample preparation methods on the results of the impedance technique in the study of platelet hyper- and hypo-function in whole blood. Thrombosis Research, 1993, 71, 89-94.	1.7	10
115	Which tests are most useful to distinguish between clonal and reactive thrombocytosis?. American Journal of Medicine, 1996, 101, 233-235.	1.5	10
116	International Prognostic Scoring System and Other Prognostic Systems for Myelodysplastic Syndromes. Blood, 1997, 90, 4232-4235.	1.4	10
117	Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients. ELife, 2021, 10, .	6.0	10
118	Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: Relevance for MYH9-related disease. International Journal of Molecular Medicine, 2006, 17, 729.	4.0	9
119	A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defect. European Journal of Medical Genetics, 2010, 53, 256-260.	1.3	9
120	Investigational drugs in thrombotic thrombocytopenic purpura. Expert Opinion on Investigational Drugs, 2011, 20, 1087-1098.	4.1	9
121	Inherited thrombocytopenias in the era of personalized medicine. Haematologica, 2015, 100, 145-148.	3.5	9
122	Mean platelet volume for distinguishing between inherited thrombocytopenias and immune thrombocytopenia – response to <scp>B</scp> eyan. British Journal of Haematology, 2013, 163, 413-414.	2.5	7
123	Clonal chromosome anomalies affecting <i><scp>FLI</scp>1</i> mimic inherited thrombocytopenia of the Parisâ€Trousseau type. European Journal of Haematology, 2012, 89, 345-349.	2.2	6
124	Cutaneous involvement by postâ€polycythemia vera myelofibrosis. American Journal of Hematology, 2014, 89, 448-448.	4.1	6
125	Desmopressin and super platelets. Blood, 2014, 123, 1779-1780.	1.4	6
126	Giant platelet syndromes and the MYH9 mutations. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2004, 10, 187-8.	1.2	6

#	Article	IF	CITATIONS
127	Treatment of inherited thrombocytopenias. Haematologica, 2022, 107, 1278-1292.	3.5	6
128	Transfection of the mutant MYH9 cDNA reproduces the most typical cellular phenotype of MYH9-related disease in different cell lines. PathoGenetics, 2008, 1, 5.	5.7	5
129	Role of splenectomy in inherited thrombocytopenias. Blood, 2004, 104, 1227-1227.	1.4	4
130	Absence of CYCS mutations in a large Italian cohort of patients with inherited thrombocytopenias of unknown origin. Platelets, 2009, 20, 72-73.	2.3	4
131	Heparin Infusion Facilitates ex vivo Spontaneous Platelet Aggregation in Patients with Acute Myocardial Infarction Who Have Undergone Thrombolytic Therapy. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1993, 23, 185-191.	0.3	3
132	Small red blood cells mimicking platelets. Blood, 2014, 123, 4014-4014.	1.4	3
133	The irreversibility of platelet aggregation is regulated by myosin IIA, but is not compromised in MYH9-related disease. Thrombosis Research, 2011, 127, 171-173.	1.7	2
134	Research at the heart of hematology: thrombocytopenias and platelet function disorders. Haematologica, 2017, 102, 203-205.	3.5	2
135	Studies with the Nanobody That Detects the Gain-of-Function of von Willebrand Factor in a Cohort of Patients with Type 2B von Willebrand Disease: Correlation with Platelet Count, VWF Multimers and Molecular Defects Blood, 2006, 108, 1011-1011.	1.4	2
136	Thrombopoietin (TPO) Levels in Inflammatory Disorders with or without Reactive Thrombocytosis Blood, 2006, 108, 1111-1111.	1.4	1
137	Spontaneous splenic rupture due to extramedullary haematopoiesis in a patient with inherited thrombocytopenia. Blood Transfusion, 2021, 19, 257-260.	0.4	1
138	Anomalous Erythrocytes Produced by Rabbits with Liver Damage. Hoppe-Seyler's Zeitschrift Für Physiologische Chemie, 1982, 363, 1341-1346.	1.6	0
139	An introduction to thrombotic thrombocytopenic purpura. Transfusion Science, 1992, 13, 5-12.	0.6	0
140	Reticulated platelets in primary and reactive thrombocytosis: a reply. British Journal of Haematology, 1998, 101, 389-389.	2.5	0
141	Dissecting clinical findings: platelet defects segregate independently of deafness and cataract in a family affected by an apparent syndromic form of macrothrombocytopenia. International Journal of Molecular Medicine, 2005, 16, 437.	4.0	0
142	The Case Proteinuria and low platelet count. Kidney International, 2012, 81, 927-928.	5.2	0
143	Inherited Thrombocytopenias. , 2017, , 727-747.		0

Heterozygous Ala156Val Mutation in the GPIb Alpha (Heterozygous Bernard-Soulier Syndrome Type) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1 1.4 0 1233-1233.